▶ HEXARELIN · SUBTOPIC · DOSING LITERATURE
HEXARELIN Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of HEXARELIN. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for HEXARELIN reports the following route(s) of administration: Subcutaneous (research), Intranasal (clinical literature). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of HEXARELIN.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for HEXARELIN of approximately ~70 minutes. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of HEXARELIN. Refer to the original publication for full protocol detail.
- Imbimbo BP, Mant T, Edwards M, et al. (1994) reports the HEXARELIN protocol used in Hexarelin: A new growth hormone-releasing peptide, published in J Clin Endocrinol Metab. See the source for the protocol-level dose range, frequency, and duration. link
- Bisi G, Podio V, Valetto MR, et al. (1999) reports the HEXARELIN protocol used in Hexarelin · A new GH-releasing peptide with cardiotropic activity, published in Eur J Endocrinol. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ Hexarelin vs ipamorelin · which is stronger?
Hexarelin has higher peak GH-releasing activity per dose. Ipamorelin has higher selectivity (no significant cortisol/prolactin elevation). Hexarelin's stronger pulse comes with stronger stress-hormone elevation and faster receptor desensitization with chronic dosing.
▶ What is the half-life of hexarelin?
Approximately 70 minutes plasma half-life, longer than GHRP-2 and GHRP-6. Once-daily dosing is the typical research protocol.
▶ Does hexarelin cause receptor desensitization?
Yes. Chronic daily dosing produces faster GHS-R1a desensitization than other GHS in animal models. Research protocols typically use shorter cycles or pulsed dosing to preserve responsiveness.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Research-use only.
WADA · Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25